VERONA PHARMA PLC - ADR (VRNA) Stock Analyst Ratings
USA - NASDAQ:VRNA - US9250501064 - ADR
106.91 USD
+0.12 (+0.11%)
106.94 USD
+0.03 (+0.03%)
ChartMill assigns a Buy % Consensus number of 69% to VRNA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 108.43. This target is 1.42% above the current price.
VRNA was analyzed by 18 analysts. The buy percentage consensus is at 69. So analysts seem to be have mildly positive about VRNA.
In the previous month the buy percentage consensus was at a similar level.
VRNA was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-07-14 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-07-10 | BTIG | Downgrade | Buy -> Neutral |
| 2025-07-10 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2025-07-09 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2025-07-09 | Jefferies | Downgrade | Buy -> Hold |
| 2025-07-01 | Wolfe Research | Initiate | Outperform |
| 2025-06-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-06-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-06-18 | Roth Capital | Reiterate | Buy -> Buy |
| 2025-06-11 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-06-11 | Jefferies | Maintains | Buy -> Buy |
| 2025-06-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-28 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-12 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-01-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-10 | Roth MKM | Initiate | Buy |
| 2025-01-08 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-01-08 | Truist Securities | Reiterate | Buy -> Buy |
| 2024-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2024-11-05 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-11-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-09 | Truist Securities | Maintains | Buy -> Buy |
| 2024-10-03 | Wells Fargo | Initiate | Overweight |
| 2024-10-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-22 | Canaccord Genuity | Maintains | Buy -> Buy |
VERONA PHARMA PLC - ADR / VRNA FAQ
What do analysts expect the price target to be for VERONA PHARMA PLC - ADR (VRNA)?
18 analysts have analysed VRNA and the average price target is 108.43 USD. This implies a price increase of 1.42% is expected in the next year compared to the current price of 106.91.
How do analysts rate VERONA PHARMA PLC - ADR (VRNA)?
The consensus rating for VERONA PHARMA PLC - ADR (VRNA) is 68.8889 / 100 . This indicates that analysts generally have a neutral outlook on the stock.